Low-grade Oncocytic Tumor of the Kidney: Imaging Features of a Novel Tumor Entity

Overview

Journal Abdom Radiol (NY)

Publisher Springer

Specialties Gastroenterology
Radiology

Date 2024 Jul 28

PMID 39068611

Authors

Sylvain Bodard

Christophe Delavaud

Charles Dariane

Idris Boudhabhay

Nour El Imane Bensenouci

Marc-Olivier Timsit

Jean-Michel Correas

Virginie Verkarre

Olivier Helenon

Affiliations

Soon will be listed here.

Abstract

Purposes: Low-grade oncocytic tumor (LOT) is a rare renal tumor that has emerged from the spectrum of eosinophilic/oncocytic renal tumors and poses a diagnostic challenge due to its similarity to chromophobe renal cell carcinoma (CHRCC) and renal oncocytoma (RO). The imaging features of this novel tumor entity have not yet been clearly described. The purpose of this study was to describe the imaging features of LOT with radiologic-pathologic correlation.

Methods: We conducted a retrospective observational study involving two expert centers. We identified 12 pathologically proven LOT with preoperative imaging available, including at least computed tomography (CT) or magnetic resonance imaging (MRI), from the past 12 years. Three experienced radiologists performed the imaging analysis independently.

Results: All tumors presented well-defined borders. Nine of the 12 LOT exhibited an early peripheral enhancement with complete or almost complete centripetal fill-in on nephrographic or delayed phases without any particular shape. Three showed a homogeneous contrast enhancement. Macroscopic fat and calcifications were not observed in any of the tumors.

Conclusion: Early peripheral enhancement with complete or almost complete centripetal fill-in on nephrographic or delayed phases without any particular shape suggests a LOT diagnosis. Further analyses involving larger studies are needed to fully confirm these imaging characteristics. To date, a percutaneous biopsy should be performed before considering management.

References

Trpkov K, Williamson S, Gao Y, Martinek P, Cheng L, Sangoi A . Low-grade oncocytic tumour of kidney (CD117-negative, cytokeratin 7-positive): a distinct entity?. Histopathology. 2019; 75(2):174-184. DOI: 10.1111/his.13865. View

Hes O, Michalova K, Pivovarcikova K . New insights in the new WHO classification of adult renal tumors. Cesk Patol. 2022; 67(4):187-191. View

Trpkov K, Williamson S, Gill A, Adeniran A, Agaimy A, Alaghehbandan R . Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. Mod Pathol. 2021; 34(6):1167-1184. DOI: 10.1038/s41379-021-00737-6. View

Mansoor M, Siadat F, Trpkov K . Low-grade oncocytic tumor (LOT) - a new renal entity ready for a prime time: An updated review. Histol Histopathol. 2022; 37(5):405-413. DOI: 10.14670/HH-18-435. View

Ishikawa N, Kimura N, Yoshida T, Yoshimura I, Nakahara K, Tsuzuki T . A Case of Low-Grade Oncocytic Tumor/Chromophobe Renal Cell Carcinoma (Oncocytic Variant) of the Kidney. Case Rep Pathol. 2021; 2021:6684777. PMC: 7906815. DOI: 10.1155/2021/6684777. View

Kravtsov O, Gupta S, Cheville J, Sukov W, Rowsey R, Herrera-Hernandez L . Low-Grade Oncocytic Tumor of Kidney (CK7-Positive, CD117-Negative): Incidence in a single institutional experience with clinicopathological and molecular characteristics. Hum Pathol. 2021; 114:9-18. DOI: 10.1016/j.humpath.2021.04.013. View

Akgul M, Al-Obaidy K, Cheng L, Idrees M . Low-grade oncocytic tumour expands the spectrum of renal oncocytic tumours and deserves separate classification: a review of 23 cases from a single tertiary institute. J Clin Pathol. 2021; 75(11):772-775. DOI: 10.1136/jclinpath-2021-207478. View

Hes O, Trpkov K . Do we need an updated classification of oncocytic renal tumors? : Emergence of low-grade oncocytic tumor (LOT) and eosinophilic vacuolated tumor (EVT) as novel renal entities. Mod Pathol. 2022; 35(9):1140-1150. DOI: 10.1038/s41379-022-01057-z. View

Guo Q, Liu N, Wang F, Guo Y, Yang B, Cao Z . Characterization of a distinct low-grade oncocytic renal tumor (CD117-negative and cytokeratin 7-positive) based on a tertiary oncology center experience: the new evidence from China. Virchows Arch. 2020; 478(3):449-458. DOI: 10.1007/s00428-020-02927-0. View

10.

Kapur P, Gao M, Zhong H, Chintalapati S, Mitui M, Barnes S . Germline and sporadic mTOR pathway mutations in low-grade oncocytic tumor of the kidney. Mod Pathol. 2021; 35(3):333-343. PMC: 9817016. DOI: 10.1038/s41379-021-00896-6. View

11.

Morini A, Drossart T, Timsit M, Sibony M, Vasiliu V, Gimenez-Roqueplo A . Low-grade oncocytic renal tumor (LOT): mutations in mTOR pathway genes and low expression of FOXI1. Mod Pathol. 2021; 35(3):352-360. DOI: 10.1038/s41379-021-00906-7. View

12.

Lerma L, Schade G, Tretiakova M . Co-existence of ESC-RCC, EVT, and LOT as synchronous and metachronous tumors in six patients with multifocal neoplasia but without clinical features of tuberous sclerosis complex. Hum Pathol. 2021; 116:1-11. DOI: 10.1016/j.humpath.2021.06.002. View

13.

Salles D, Asrani K, Woo J, Vidotto T, Liu H, Vidal I . GPNMB expression identifies TSC1/2/mTOR-associated and MiT family translocation-driven renal neoplasms. J Pathol. 2022; 257(2):158-171. PMC: 9310781. DOI: 10.1002/path.5875. View

14.

Zhang H, Xia Q, Wang S, Shi M, Wang S . Low-grade oncocytic tumor of kidney harboring TSC/MTOR mutation: clinicopathologic, immunohistochemical and molecular characteristics support a distinct entity. Virchows Arch. 2022; 480(5):999-1008. DOI: 10.1007/s00428-022-03283-x. View

15.

Williamson S, Hes O, Trpkov K, Aggarwal A, Satapathy A, Mishra S . Low-grade oncocytic tumour of the kidney is characterised by genetic alterations of TSC1, TSC2, MTOR or PIK3CA and consistent GATA3 positivity. Histopathology. 2022; 82(2):296-304. DOI: 10.1111/his.14816. View

16.

Farcas M, Gatalica Z, Trpkov K, Swensen J, Zhou M, Alaghehbandan R . Eosinophilic vacuolated tumor (EVT) of kidney demonstrates sporadic TSC/MTOR mutations: next-generation sequencing multi-institutional study of 19 cases. Mod Pathol. 2021; 35(3):344-351. DOI: 10.1038/s41379-021-00923-6. View

17.

Pivovarcikova K, Alaghehbandan R, Vanecek T, Ohashi R, Pitra T, Hes O . TSC/mTOR Pathway Mutation Associated Eosinophilic/Oncocytic Renal Neoplasms: A Heterogeneous Group of Tumors with Distinct Morphology, Immunohistochemical Profile, and Similar Genetic Background. Biomedicines. 2022; 10(2). PMC: 8869370. DOI: 10.3390/biomedicines10020322. View

18.

Mohanty S, Satapathy A, Aggarwal A, Mishra S, Sampat N, Sharma S . Oncocytic renal neoplasms with diffuse keratin 7 immunohistochemistry harbor frequent alterations in the mammalian target of rapamycin pathway. Mod Pathol. 2021; 35(3):361-375. DOI: 10.1038/s41379-021-00969-6. View

19.

Kutikov A, Uzzo R . The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J Urol. 2009; 182(3):844-53. DOI: 10.1016/j.juro.2009.05.035. View

20.

Vera-Badillo F, Conde E, Duran I . Chromophobe renal cell carcinoma: a review of an uncommon entity. Int J Urol. 2012; 19(10):894-900. DOI: 10.1111/j.1442-2042.2012.03079.x. View